Top in rheumatology: FDA approval of Cyltezo, arthritis burden in US
Click Here to Manage Email Alerts
The FDA recently approved Cyltezo as the first interchangeable biosimilar for certain inflammatory diseases, allowing prescribers to substitute it for Humira without a prescription change. It was the top story in rheumatology last week.
Another top story was about new data on the prevalence of arthritis and arthritis-related activity limitation. Kristina A. Theis, PhD, said the number of adults with arthritis and whose activities are limited due to arthritis is “increasing faster than projected.”
Read these and more top stories in rheumatology below:
FDA approves Cyltezo as first interchangeable biosimilar for inflammatory disease
The FDA has designated Cyltezo the first approved interchangeable biosimilar to treat certain inflammatory diseases, allowing pharmacists to substitute it for Humira without the need for the prescriber to alter the prescription. Read more.
Nearly one-quarter of US adults have arthritis; 43% of those report activity limitations
An estimated 58.5 million adults in the United States — nearly one-quarter of the country’s adult population — had arthritis, while 25.7 million demonstrated arthritis-related activity limitations, during 2016 to 2018, according to data. Read more.
Walking tops list of exercises among adults with arthritis engaged in physical activity
Among patients with arthritis who engaged in physical activity in the past month, about 71% reported walking as one of their two most frequent activities, followed by gardening and weightlifting, according to CDC researchers. Read more.
EULAR: Tocilizumab plus glucocorticoids benefits COVID-19 cases requiring oxygen
Tocilizumab plus glucocorticoids is beneficial for patients with COVID-19 who require oxygen therapy, according to updated EULAR “points to consider” on the use of immunomodulatory therapies in SARS-CoV-2. Read more.
Vaccinated yet vulnerable: COVID-19 and the immunocompromised patient
Nothing is easy in the management of COVID-19. Similarly, nothing is easy in managing immunocompromised patients. Marry the two and the challenges more than double. Read more.